Can GHRP-2 be stacked with other nootropics?

Yes, and it is commonly paired. The cleanest pairings are with compounds on complementary pathways — anxiolytic (selank), neurotrophic (semax), sleep-architecture (DSIP), or anti-inflammatory (LL-37) — rather than with other compounds engaging the same pathway.

Cognitive side effects to watch for?

Reported issues are uncommon in animal and limited human data but include mild sedation, vivid dreams, transient mood lability in the first week, and infrequent headache. There are no large-scale human safety trials. Discontinue if mood symptoms are concerning and re-evaluate.

Is GHRP-2 a true nootropic?

Not in the caffeine-or-modafinil sense. GHRP-2 does not acutely sharpen attention or working memory in healthy users. Its cognitive value is restorative — supporting recovery from neurological injury, reducing chronic neuroinflammation, and stabilising the upstream systems that cognitive function depends on.

Can GHRP-2 be stacked with other nootropics?

Yes, and it is commonly paired. The cleanest pairings are with compounds on complementary pathways — anxiolytic (selank), neurotrophic (semax), sleep-architecture (DSIP), or anti-inflammatory (LL-37) — rather than with other compounds engaging the same pathway.

Cognitive side effects to watch for?

Reported issues are uncommon in animal and limited human data but include mild sedation, vivid dreams, transient mood lability in the first week, and infrequent headache. There are no large-scale human safety trials. Discontinue if mood symptoms are concerning and re-evaluate.

Is GHRP-2 a true nootropic?

Not in the caffeine-or-modafinil sense. GHRP-2 does not acutely sharpen attention or working memory in healthy users. Its cognitive value is restorative — supporting recovery from neurological injury, reducing chronic neuroinflammation, and stabilising the upstream systems that cognitive function depends on.

Is GHRP-2 a true nootropic?

Not in the caffeine-or-modafinil sense. GHRP-2 does not acutely sharpen attention or working memory in healthy users. Its cognitive value is restorative — supporting recovery from neurological injury, reducing chronic neuroinflammation, and stabilising the upstream systems that cognitive function depends on.

Cognitive side effects to watch for?

Reported issues are uncommon in animal and limited human data but include mild sedation, vivid dreams, transient mood lability in the first week, and infrequent headache. There are no large-scale human safety trials. Discontinue if mood symptoms are concerning and re-evaluate.

What is the standard dosing protocol for GHRP-2?

Conventional GHRP-2 dosing is 100-300 mcg 2-3x daily subq via subq. For cognitive and neurological use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

How does GHRP-2's half-life affect dosing?

GHRP-2 has a plasma half-life of ~15-60 min, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 2-3x daily subq dosing at 100-300 mcg per dose explains the typical onset timeline for cognitive and neurological endpoints.

What is the regulatory status of GHRP-2?

GHRP-2 regulatory status: Approved in Japan for GH stimulation testing only in the United States; WADA status banned (s2); research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For cognitive and neurological use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What class of compound is GHRP-2?

GHRP-2 is classified as a Growth hormone releasing peptide. Within this class, alternative names and analogues include Pralmorelin, KP102. The class-level pharmacology shapes both the clinical applications and the safety profile; the cognitive / neurological literature treats GHRP-2 alongside its class peers when evaluating relative merits.

How should GHRP-2 be stored and reconstituted?

Lyophilised GHRP-2 stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

Is GHRP-2 safe during pregnancy or breastfeeding?

GHRP-2, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Home/ Compounds/ GHRP-2

GHRP-2

Neuroprotection

Cognitive performance and neurological recovery applications of GHRP-2 centre on its relationship to cerebral perfusion, BDNF and NGF signalling, and the gut-brain inflammatory axis. A second-generation GHRP with stronger GH-releasing effect than GHRP-6, but more prolactin and cortisol elevation than ipamorelin. A 6-residue growth hormone releasing peptide, GHRP-2 is investigated in nootropic, post-injury, and chronic-neuroinflammation contexts; the cognitive endpoints accumulate across 4-8 weeks rather than appearing acutely.

Cognitive / Neurological Applications

Stroke RecoveryPost-TBI RecoveryHPA Axis ModulationDopamine ModulationMood Stabilisation

Key Takeaways

Cognitive lens: GHRP-2 acts as a modulator with both restorative and modest activating components for cognitive endpoints.
CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects.
Mechanism: Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs.
Neuro dose: 100-300 mcg 2-3x daily subq via subq; cognitive effects accumulate across 4-8 weeks.
Cognitive stack partners: Semax, Selank, Semax + Selank Blend.

Cognitive / Neurological Mechanism

Three pathways shape GHRP-2's cognitive profile: Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs. Stimulates a pulsatile GH release. Mildly raises ACTH/cortisol and prolactin compared to ipamorelin. Each subsection below covers one - CNS access mechanisms, neurotrophic and monoamine effects, and the inflammation-and-recovery layer that often produces the most subjectively reported cognitive shifts.

Monoamine and neurotrophic effects

GHRP-2's downstream effects on monoamine systems (dopamine, serotonin, occasionally noradrenaline) and on neurotrophic signalling (BDNF, NGF, NT-3) form the molecular substrate of its observed cognitive phenotype. Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs. Stimulates a pulsatile GH release. Mildly raises ACTH/cortisol and prolactin compared to ipamorelin. For users tracking cognitive endpoints over the typical 2-3x daily subq dosing pattern at 100-300 mcg, the changes accumulate across 4–8 weeks rather than emerging acutely. The relevant clinical endpoints are sleep quality, recovery capacity, mood stability, and resilience to cognitive stressors.

Inflammation and neurological recovery

One of the most replicated effects across compounds in GHRP-2's class (Growth hormone releasing peptide) is reduction of inflammatory cytokines (TNF-α, IL-1β, IL-6) in tissues including the central nervous system. For users whose cognitive complaints track with chronic low-grade neuroinflammation — long-COVID, post-viral cognitive fog, post-concussion lingering symptoms, chronic stress — this anti-inflammatory layer is often the most operationally relevant mechanism. GHRP-2's contribution operates on the same axis at 100-300 mcg per dose.

Cerebral perfusion and the structural cognitive substrate

Cognitive function depends on adequate cerebral perfusion, intact endothelial signalling, and a low chronic-inflammatory tone in the brain parenchyma. GHRP-2, with its Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs Stimulates a pulsatile GH release. Mildly raises ACTH/cortisol and prolactin compared to ipamorelin. mechanism, contributes to this substrate rather than producing acute stimulant-like activation. Across the cognitive applications outlined below, what users describe is restoration of baseline rather than amplification above it. The ~15-60 min pharmacokinetic profile supports this restorative rather than stimulant phenotype.

Cognitive / Neurological Applications

Chronic Neuroinflammation

Where GHRP-2 is used for chronic neuroinflammation, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.

Mood Stabilisation

Mood Stabilisation is one of the more-reported subjective benefits of GHRP-2 across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.

HPA Axis Modulation

For hpa axis modulation, GHRP-2 is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.

Anxiety

Where GHRP-2 is used for anxiety, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100-300 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60-300 mcg	4–6 weeks initial cycle
Neuroprotection focus	SubQ	100-300 mcg	2-3x daily SubQ
Maintenance phase	SubQ	70-300 mcg	Ongoing with periodic pauses

Dose timing for GHRP-2 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

GHRP-2 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.

GHRP-2 + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with GHRP-2's mechanism in cognitive / neurological protocols.
GHRP-2 + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with GHRP-2's mechanism in cognitive / neurological protocols.
GHRP-2 + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with GHRP-2's mechanism in cognitive / neurological protocols.
GHRP-2 + DSIP: Mechanism remains incompletely characterised. Pairs naturally with GHRP-2's mechanism in cognitive / neurological protocols.

Safety & Regulatory Status

WADA: Banned (S2) FDA: Approved in Japan for GH stimulation testing only

More prolactin/cortisol effect than ipamorelin. Pair with GHRH for synergy.

Lens-specific safety considerations for cognitive / neurological use of GHRP-2: More prolactin/cortisol effect than ipamorelin. Pair with GHRH for synergy. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

GHRP-2 mechanism of GH secretion

PMID 12679487

Supporting

Pralmorelin / GHRP-2 clinical use

PMID 10221681

GHRP-2 vs Related Peptides

Compound	Profile	Onset	Best For
GHRP-2	Growth hormone releasing peptide	~15-60 min	Neuroprotection
Semax	ACTH-derived nootropic heptapeptide	CNS effect hours; plasma minutes	A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent
Selank	Tuftsin-derived heptapeptide anxiolytic	CNS effect lasts hours; plasma short	A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder
DSIP	Neuropeptide (sleep)	~7 min plasma; CNS effects longer	A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience
Pinealon	Khavinson tripeptide (pineal-derived)	Short plasma; durable tissue effects	A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models

Frequently Asked Questions

Does GHRP-2 cross the blood-brain barrier?

Direct BBB passage is variable across peptide compounds and is rarely the dominant mechanism. GHRP-2 produces CNS effects through some combination of: direct BBB transport (at low efficiency for most peptides), vagal-afferent gut-brain axis signalling, and effects on cerebral vasculature where the barrier is locally compromised. The CNS effects observed in research consistently appear at peripheral doses, supporting the indirect-access framework.

How long until I notice cognitive effects?

Mood and gut-related symptoms often shift within 5–14 days. Cognitive recovery and inflammation-related changes accumulate across 4–8 weeks. Stimulant-like 'feel it today' effects are not the typical GHRP-2 profile; the compound is restorative rather than acutely activating.

Is GHRP-2 appropriate alongside SSRIs or other psychiatric medications?

GHRP-2's pharmacology is generally additive rather than competitive with most psychiatric medications, but the combined modulation of monoamine systems warrants supervision. Users on SSRIs, SNRIs, lithium, or atypical antipsychotics should consult their prescriber before adding GHRP-2 to the regimen.

Best route for cognitive applications — injection or oral?

For most GHRP-2 cognitive use cases, the route that delivers the compound closest to its target site of action is preferred. Subcutaneous administration provides reliable systemic exposure and is the default route in most cognitive research protocols.

What is GHRP-2?

GHRP-2 (also known as Pralmorelin / KP102) is a 6-residue growth hormone releasing peptide with a molecular weight of 817 Da and a plasma half-life of ~15-60 min. Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs. Stimulates a pulsatile GH release. Mildly raises ACTH/cortisol and prolactin compared to ipamorelin. The compound is studied primarily in the cognitive / neurological domain for the applications outlined above.

What should I look for in GHRP-2 sourcing and quality?

Acceptable GHRP-2 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 817 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Clinical Protocol

Start a GHRP-2 Protocol

Alukard provides physician-supervised cognitive protocols with GMP-certified GHRP-2 and GMP-certified compounds and comprehensive neurological assessments.

Get Protocol

Quick Facts

Molecular weight: 817 Da
Sequence length: 6 aa
Half-life: ~15-60 min
WADA: Banned (S2)
FDA: Approved in Japan for GH stimulation testing only

Stack Partners

Semax

Selank

Semax + Selank Blend

DSIP

LL-37

Research Note

All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for GHRP-2 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised cognitive protocols

Start Your Cognitive / Neurological Protocol for GHRP-2

Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised